Login
$BRVE
$19.49 +$0.00 (0.0%) After hours

$BRVE 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

06 Nov 2026 8-K: Regulation FD Disclosure

Hengrui Pharma and Braveheart Bio Present Data from52-Week Open-Label Extension of Phase 2 Studyof HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

08 Sep 2026 8-K: Results of Operations and Financial Condition

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated

07 Aug 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or i...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support